Published in Actas Urol Esp on July 14, 2011
Current status of radical prostatectomy for high-risk prostate cancer. Korean J Urol (2014) 0.83
Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol (2012) 0.79
Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysis. Br J Cancer (2014) 0.77
Clinical Effect of Switching from a Luteinizing Hormone-Releasing Hormone Agonist to an Antagonist in Patients with Castration-Resistant Prostate Cancer and Serum Testosterone Level ≥ 20 ng/dl. Curr Urol (2016) 0.77
Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update. Prostate Cancer Prostatic Dis (2017) 0.75
Radium-223 for the treatment of castration-resistant prostate cancer. Onco Targets Ther (2015) 0.75
Hormonal therapy in metastatic prostate cancer: current perspectives and controversies. Oncol Rev (2013) 0.75
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol (2013) 7.48
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol (1998) 3.69
Canopy nitrogen, carbon assimilation, and albedo in temperate and boreal forests: Functional relations and potential climate feedbacks. Proc Natl Acad Sci U S A (2008) 3.37
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J Urol (1993) 3.31
Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol (1992) 3.30
Azathioprine in rheumatoid arthritis. Br Med J (1969) 3.14
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol (2010) 3.00
Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer (1993) 2.99
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol (2001) 2.55
Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet (2001) 2.44
Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet (2000) 2.26
Quantitative study of doctor-patient communication. Q J Med (1969) 2.25
Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol (1997) 2.23
In vivo and in vitro complex formation of prostate specific antigen with alpha 1-anti-chymotrypsin. Prostate (1995) 2.07
PROCAM-, FRAMINGHAM-, SCORE- and SMART-risk score for predicting cardiovascular morbidity and mortality in patients with overt atherosclerosis. Vasa (2010) 2.07
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine (2001) 2.06
Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol (2013) 1.97
Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med (1983) 1.89
EAU guidelines on prostate cancer. Eur Urol (2005) 1.88
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol (2005) 1.85
The prosome: an ubiquitous morphologically distinct RNP particle associated with repressed mRNPs and containing specific ScRNA and a characteristic set of proteins. EMBO J (1984) 1.67
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology (2009) 1.65
Predicting the onset of net carbon uptake by deciduous forests with soil temperature and climate data: a synthesis of FLUXNET data. Int J Biometeorol (2005) 1.64
Somatic mutations of KIT in familial testicular germ cell tumours. Br J Cancer (2004) 1.64
Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ (1992) 1.63
Sacral colpopexy with concurrent Burch colposuspension in patients with vaginal vault prolapse. Urol Int (2006) 1.60
Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) Ann Oncol (1998) 1.60
EORTC Late Effects Working Group. Late Effects toxicity scoring: the SOMA scale. Int J Radiat Oncol Biol Phys (1995) 1.59
EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Radiother Oncol (1995) 1.58
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Ann Oncol (2003) 1.53
Coordinate activation of lysosomal, Ca 2+-activated and ATP-ubiquitin-dependent proteinases in the unweighted rat soleus muscle. Biochem J (1996) 1.52
Hyperfractionated compared with conventional radiotherapy in oropharyngeal carcinoma: an EORTC randomized trial. Eur J Cancer (1990) 1.50
A 1-y trial of the effect of high-selenium bread on selenium concentrations in blood and toenails. Am J Clin Nutr (1993) 1.50
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
Focal therapy in prostate cancer-report from a consensus panel. J Endourol (2010) 1.43
Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.43
[Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study]. Aktuelle Urol (2006) 1.42
Plasma bubble formation induced by holmium laser: an in vitro study. Urology (2004) 1.42
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med (2016) 1.41
Endobronchial metastatic disease: analysis of 32 cases. J Surg Oncol (1996) 1.40
Determination of pre-orchiectomy serum levels of alpha-fetoprotein and human choriogonadotrophin in testicular cancer. Br J Urol (1992) 1.39
[Corticoid treatment in Castleman's disease]. Med Clin (Barc) (1995) 1.39
The Stratified Subsidence of Fine Particles. Proc Natl Acad Sci U S A (1923) 1.38
[Update of the study on survival with early hormonal therapy associated with radiotherapy (EORTC 22863 Study) in patients with advanced prostatic cancer. Interview with Michel Bolla]. Recenti Prog Med (2001) 1.36
Self-injurious behavior: a state-wide prevalence survey of the extent and circumstances. Appl Res Ment Retard (1986) 1.34
Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer (2000) 1.33
Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol (1999) 1.33
Prosomes. Ubiquity and inter-species structural variation. J Mol Biol (1986) 1.33
Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer (1998) 1.30
Age is not a limiting factor for radical radiotherapy in pelvic malignancies. Radiother Oncol (1997) 1.29
Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol (1996) 1.29
Methicillin-resistant Staphylococcus aureus: experience in a general hospital over four years. Am J Epidemiol (1982) 1.28
Environmental controls on sap flow in a northern hardwood forest. Tree Physiol (2005) 1.28
Periapical status, prevalence and quality of endodontic treatment in an adult French population. Int Endod J (2002) 1.25
Respiratory carbon losses and the carbon-use efficiency of a northern hardwood forest, 1999-2003. New Phytol (2005) 1.24
An evaluation of case management. Am J Public Health (1987) 1.24
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer (2011) 1.22
Tobacco smoking, body mass index, hypertension, and kidney cancer risk in central and eastern Europe. Br J Cancer (2008) 1.20
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Rheumatoid arthritis and ankylosing spondylitis occurring together. Br Med J (1976) 1.18
Giant calculus of the posterior urethra following recurrent penile urethral stricture. Urol Int (2002) 1.16
The prevalence and predictors of psychological distress in patients with early localized prostate cancer. BJU Int (2002) 1.14
Heat shock increases the synthesis of the poly(A)-binding protein in HeLa cells. Proc Natl Acad Sci U S A (1985) 1.13
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol (2011) 1.11
Crystal synovitis. J Bone Joint Surg Br (1966) 1.10
Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol (2006) 1.10
Search for a W' or techni-ρ decaying into WZ in pp Collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2012) 1.10
Value of cytoprognostic classification in breast carcinomas. J Clin Pathol (1986) 1.10
Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol (2003) 1.09
Search for new physics with same-sign isolated dilepton events with jets and missing transverse energy. Phys Rev Lett (2012) 1.09
A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine (2008) 1.08
Search for supersymmetry at the LHC in events with jets and missing transverse energy. Phys Rev Lett (2011) 1.08
Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination. Urology (2001) 1.07
[Primary non-Hodgkin's lymphoma of the breast]. Med Clin (Barc) (1993) 1.07
Search for stopped Gluinos in pp collisions at square root s=7 TeV. Phys Rev Lett (2011) 1.07
Quality assurance issues in radical prostatectomy. Eur J Surg Oncol (2005) 1.06
Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostics factors. Int J Radiat Oncol Biol Phys (1997) 1.06
A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer (2005) 1.06
Possible involvement of messenger RNA-associated proteins in protein synthesis. J Cell Biol (1982) 1.06
Cellular and molecular pathology of prostate cancer precursors. Scand J Urol Nephrol Suppl (2000) 1.06
Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer. Cochrane Database Syst Rev (2000) 1.05
Prognostic risk factors in low stage testicular germ cell tumors: unanswered questions regarding clinically useful prognosticators for extratesticular disease. Cancer (1997) 1.05
Odontometrical method useful in determining gender and dental alignment. Forensic Sci Int (2001) 1.05
TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. Cancer Lett (2010) 1.05
Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol (2011) 1.05
Measurement of the Υ1S, Υ2S, and Υ3S polarizations in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2013) 1.05
[Carcinoembryonic antigen in breast tumors: initial evaluation and monitoring]. Bull Cancer (1983) 1.04
Clinical impact of dosimetry quality assurance programmes assessed by radiobiological modelling of data from the thermoluminescent dosimetry study of the European Organization for Research and Treatment of Cancer. Eur J Cancer (2000) 1.04
Stereo-specific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cell lines. Cancer Lett (1999) 1.04